CNST - Earnings call transcript Q3 2020 | Constellation Pharmaceuticals Inc

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by. And welcome to the Constellation Pharmaceuticals Third Quarter 2020 Earnings Conference Call. [Operator Instructions]. I would now like to hand the conference to your speaker today, Kia Khaleghpour, Vice President of Investor Relations and Communications. Please go ahead, ma'am.

Kia Khaleghpour

Financial Operational XXXX Quarter Third Results Performance. and Constellation's morning Raythatha, Constellation's in our Executive Jigar this call Participating Chief are Officer; Dr. Chief Jeff our Medical Dr. Humphrey, Officer; our Patrick Financial our Chief Officer; Emma Trojer, Scientific Officer. Reeve, and Chief Slide X. Please turn to

now well presentation Factors Before we to uncertainties uncertainties. and the recent discussion over to include including want call as quarterly and various begin, Actual subject including other described XX, section results this statements, are important the the I risks Jigar. for materially company's to And those we company's ended quarter today due important factors Exchange will risks filings that which to most potential point forward-looking certain in which turn will out report I the XX-Q as earlier XXXX, our Securities Risk the with and may in Form September on of the filed Commission, differ factors, morning.

Jigar Raythatha

to and Thank good Kia, X. you, Please morning, turn Slide everyone.

overview an with begin of Let's Constellation.

a We are fully building company. pharmaceutical integrated

roots of is next commercialize the our is programs, own that The in believe clinical that the we for and preclinical we've and made all with we Our and are have advancements a discovery sustainable. now to pipeline homegrown, launch step company which with our are therapeutics.

with impactful hematology target. EZHX in and to we oncology continuing addressable translates to population therapies are invest care hard best-in-class myelofibrosis working in with patient As doing with right disease-modifying we therapeutics potential therapy standard And of We're to a our this against what also for now, that how to inhibitor CPI-XXXX are a into the we the platform. expand aimed novel discovery transform and also with deliver therapy. potential

it we CPI-XXXX please. about by to take the team. X, is to Slide Turn our continuing this Constellation Today, grow have to from made that updates CPI-XXXX you'll of All and the to level. we and are next built, management team strong possible hear

gearing recap will upcoming far medical what the at as Humphrey, CPI-XXXX in Jeff study Officer, Medical to weeks. MANIFEST meeting from couple we're so the you've Chief of Our up seen present what a as in ASH well

will our share differentiated initiate. the Officer, you for review of Scientific that with the will some behind soon Trojer, EZHX about believe will development Patrick opportunity. behind compound we the how best-in-class study with CPI-XXXX, into Jeff addition, you will Chief our to In tell that details we Phase inhibitor. which be translates a the science you He and plans III

talk about the this, months. a CPI-XXXX to the bone shown those ASH turn like more Beyond with have the disease-modifying that to we pipeline, has therapy. been profile we upcoming CPI-XXXX please. this very On a in Turn spleen very you to the on robust Slide to pleased we We've will X, I'd which preclinical that remind the focused volume potential be and with on improvement, anemia we're believe I'd reduction also blood we're all symptom and to slide, here modification. that, that But marrow at to X presenting we've over to are red excited like about seen and on believe measures. cell point call together improvements the Medical for data Meeting we potential in biology, highlight fibrosis. measures that observing translational Jeff. the We disease taken And the impact

Jeff Humphrey

Jigar. Thanks,

has X. say disease. was in spleen and receiving with to X. Please CPI-XXXX at Arm to time. shows ruxolitinib X, rates JAK evaluable turn in of respectively. to X, preliminary patients, I'm ruxolitinib Arms consistently Arm turn XX pleased XX% that In III X, disease. subjects. CPI-XXXX to with XX% of Phase X presented naive Arm JAK first SVRXX with motivated myelofibrosis. Slide to first CPI-XXXX first-line Let Please trial. in randomized MANIFEST trial completed on or monotherapy patients patients our a as have to is naive X ruxolitinib X rates compare in The and XX that response patients plus These and XX-week given as rates volume approximately to data the line This of inhibitor Slide historical XX% response rate In spleen to given start date accrual Arm in in Please over inhibitor trials add-on favorably XX volume data slide of Slide second-line XXX we II prior me key XX% review patients from Phase ruxolitinib. us experienced CPI-XXXX. combination is turn is to with X. high In

the summary X. thrombocytopenia. both profile in is CPI-XXXX of and on-target Here is of ruxolitinib reported The Arm a safety toxicity

CPI-XXXX you Preliminary receiving demonstrated in data are single for other XXX of is see the well a therapy were agent significantly promising. setting. myelofibrosis rate of here, Cohort response we SVRXX rates in as Grade As Xb, that rate relatively X. X higher turn In are low than second-line an believe agents generally Please higher, and can second-line XX%, the second-line and to tolerated. combination a patients the Slide combination also monotherapy

for disease-modifying to symptom patients Cohorts changes are XX% total of signals fibrosis spleen at XX in and independence, CPI-XXXX, scores, which preliminary Xa transfusion-dependent Xa transfusion in CPI-XXXX. transfusion XX. to and of respectively. weeks, We that Slide achieved conversions potential conversion believe of a of the volume, include addition, XX% and In Please rates data in bone reductions effect independence to improvements marrow turn

the new be presented MANIFEST in updating not be Please clinical be ASH ASH December. that to We data, will November will data the meeting our itself will at at in data abstracts the XXXX. from new note contain published

will for December in Arm X Srdan data presentations X Drs. Mascarenhas oral XX-week respectively. on be and separate Arm discussed New X and by John Verstovsek,

new be reviewed and also and discuss poster X. cellularity data, MANIFEST We Slide in from at XX-week of new X. will The Arm event investor will will second in clinicians X X. will on an key in Please turn changes MANIFEST on discussion by XX. a bone enrolled marrow and fibrosis X One trials-in-progress with including data X. poster to will also design discuss patients December poster December present data the posters A discuss translational XX-week

Our first-line include to to rux to to set approximately trial ruxolitinib experience will our turn second-line at as or continues grow. patients. III on conduct support include data myelofibrosis patients. decision a myelofibrosis at for CPI-XXXX in Please will XX XX pivotal data ASH XX-week XX to XXX XX. approximately for data first-line data in XXX monotherapy The XXX with XX-week The in Slide to for myelofibrosis data ASH The set Phase add X. MANIFEST for

a CPI-XXXX patients fourth X:X naive randomized study We've site quarter. plus plus in JAK secondary initiation advanced ruxolitinib pivotal primary inhibitor myelofibrosis symptoms versus be or first splenomegaly begun the have reminder, will patient placebo is with and blinded, requiring trial remain a Approximately activities in disease our randomized and therapy. with As ruxolitinib. dose patients XXX to the on to track who

We continue trial. clinical Patrick, hand to to my to over executing be now discuss call important And colleague, on this the CPI-XXXX. focused I'll Patrick?

Patrick Trojer

Slide Thank you, to Jeff. Please turn XX.

CPI-XXXX that attention another research inhibitor turn internal The As oncology your from discovery I candidate CPI-XXXX. stems to would like efforts, EZHX platform. from Constellation's product now to our has emerged

excited be clinic. about to of the program continue the this in We progress

genes. can residence to ways, Its long of histone time activity an number now EZHX maintaining to CPI-XXXX and driver inducing specific is is designed application We and cooperates on own potency, suppress exposure EZHX sets to that EZHX expression inhibitors of of believe a where histone established potential that by is of has and a as We profile, in prostate CPI-XXXX including pursue of lysine such very methylate broad clinical oncogenic try where role With EZHX levels to generation where Doubling EZHX EZHX EZHX inhibitor. increased pathway on the driver metabolism. HX inhibition. of with the the in methyltransferase. and shown not a oncogenic have inhibitors cancer. be recall we that down will thereby You its XX already type case improve best-in-class first a or context

in presents chemotherapeutic to synthetic of in We excited whether XX. the tumor can longer induced that acquired metabolism. tumor CPI-XXXX which residence we think of the supported compared agents key panel which that's slide other off The periods first potency, potency CPI-XXXX potential: turn of is lack left CPI-XXXX, of also biochemical are data on important here, And cells coverage binds promote table XX/X microenvironment you properties The generation and reprogram to component designed to superior increased an X we target demonstrates resistance time as for inhibitors. context driving for of a for potential the come achieve best-in-class corroborates stage of EZHX one CPI-XXXX to matter see the Slide drug middle explore because off properties can key to illustrates tumor that whereas We exploit relationships. Please the clinical sensitize and to lethal This time, extended immunity. inhibitors after EZHX of and hours. EZHX, come it doesn't to efficacy. CPI-XXXX the

certain slide solid some of lymphoma, not the therapeutic context BAPX, the or compound biology. believe observed turn for of With CPI-XXXX right, This DX function in days in This treatment. functional CPI-XXXX the maintenance the function potential administered as consistent left of to interested EZHX. on metabolism indications. as extract EZHX the tumor ARIDXA of molecular create of the exposure dosing, aberrations XX its illustrates profile, that highlights that gain On single of once-daily see in of with Such in state at on and of in a does profile EZHX the the is this CPI-XXXX. XX. context Slide full exposure as several loss after orally the initial CPI-XXXX genomic subsets cartoon induce The DXX. course observation may to such own itself we're we development with Please observed dose, of can dependence where mice you mutations of steady after for over mutations

prostate AR We of interested or androgen exploration be as the of to cooperation EZHX an with receptor functional inhibitors where seen indication we targeted continue CPI-XXXX, cancer repeatedly for have in agents.

EZHX interested chemotherapeutic tumors resistance. Schlafen addition, illustrated In are of gene. XX drug data that Schlafen reactivation in expression we to And resynthesizes the the acquired suppresses XX Preclinical agents.

with drug Slide please. XX, So or to reverse resistance. acquired by combining prevent could Turn CPI-XXXX agents, one potentially chemotherapeutic

properties of those cancer on give show we X that tumor preclinical data CPI-XXXX examples Now the have CPI-XXXX favorable one with Its in opportunity let right. in potency, by comprehensive On mutation the allow mouse and function EZHX to genetics, with performance daily of loss superior the responses ARIDXA EZHX some residence to regression on addressed the models on me engagement first time to you and cancers long In slide, gain shown other by achieved and patient function in inhibitor. contexts. in hematologic tumors studies, demonstrates this seen of expand mutation both a adequately target various the once populations may vivo its that of solid left schedule. CPI-XXXX a EZHX efficacy we dosing of achieved contexts us breadth deeper harness of not in generation

study CPI-XXXX escalation patient We dose a are in I currently an in all-comers accepting Phase population.

and exposure completed multiple have increase metabolism. We of induction no of compound cohorts seen and in a evidence dose-dependent dose

measured We seen increases in markets. as of by assessment multiple have also dose-dependent pharmacodynamic target engagement

possible continue the to later it's we will the dose. recommended this year. reach Phase while dose dose We the II Phase determine to tail that in end still are escalate a of And II year, we

to Phase take excited Emma are I hypothesis biomarker the our in now of to several II. We invite test floor. And

Emma Reeve

in Slide to quarter. with line substantially Thanks, use both costs complete attributable XX, commercial let's results MANIFEST which was to compared by which increased with year work turn in cash million were to our third $X.XX loss third of marketable per as $X.XX quarter, launch build equivalents compound. the trials and fund plan We third CPI-XXXX. with for compared million expenses Personnel resources Patrick. the Phase net cash, to loss our out $X.X in of and was our to for build common million in clinical securities quarter $XX.X prior mainly the these per Please financing a related and the due the expectations. to quarter the stockholders we With increased our share net and into year-over-year, to quarter had operations of and needed R&D the expect XX, in share financial XXXX. X, June, The as to review our will CPI-XXXX, our II Phase organization our $XXX.X organization. to We we III September mid-XXXX. continue MANIFEST respectively, also

discovery CPI-XXXX CPI-XXXX the the are In cash forward To progress and ASH We MANIFEST to at the platform. as to upcoming addition, trial X. us new as well presenting I/II allow dosing support for clinical to pleased data patients start our with of meeting, our conclude, look will making. in we complete to very Phase we're

program, updates along our the part program. initiating of making the II and the For forward to that recommended we're look CPI-XXXX you further We progress study. determining Phase the towards way on giving dose

So you over the things with operator. back that, I'll line the for would to turn open now please Operator, questions.

Operator

Instructions]. [Operator

Our with first Rama JPMorgan. Anupam question from comes

Anupam Rama

quick ones. really two Just

the are timelines. like gating didn’t an So additional MANIFEST what ET? second a running X the later or and today XXX see the Maybe getting enrolling in on release to this final And there anything up patients indications factors in and question, on slides quarter? update in just

Jigar Raythatha

to timing. to over just on then on Maybe question quickly first it turn and touch second the your answer question I'll first, Jeff I'll

we aiming selection, work the track. work start thrombocythemia, of to the protocol POC on We're through start earlier are going we are to in study site operations writing, We is enrolling that essential a happen announced -- that patients. that kind all

with And of anticipate so will CPI-XXXX we we've off the may also that being myeloid to able it indications next the uncovered likely shortly. months. some to kick that And begin do X be with XX there in that to other that biology do

you in Jeff, kind And of X comment want the so and stand track. on do where of progress And kind with initiation? that's all on MANIFEST things to

Jeff Humphrey

Yes. Thanks, Jigar.

a execution the second final As We're And on listed X. trial we're a and much now start for on the MANIFEST rapid on preparations we've start. you track of know, at focused And half design. we're very clinicaltrials.gov very in site.

Operator

Abrahams question Our with Brian Markets. from comes next Capital RBC

Brian Abrahams

I questions from few A me, could. if

I What data for be translational poster clinical to of off, a mentioned First we usage know -- going on the if but What focus how drug, becomes lot XXX. ASH, the you there's how on earlier a should available? at think And ultimately it there? there's that is bar? be of be to should going about you data for think to for stage do looking going we important be the data

Jigar Raythatha

Yes.

CPI-XXXX. together effects seeing ASH, first with biology anything the we data that. add the start growing meetings red that to that add, mechanism start at at kind of scientific way I cell translational disclosures that to of with I'll over of would at course So back of it's the the we'll to myeloid maybe, and the impact has set And you is next Brian, really kind comes that look several that the tie believe Patrick of again, we're to clinical can have then the biology. with on the it action play and potential blood of

want about bit to to we is I talked kind start of into think fibrosis disclosure to on compares peel to about so of more. kind of look would We ASH the you dig kind might beyond starting kind the mechanism but future? -- little that the And and Patrick, way date, we in samples -- in anything a it's to to patient bone what add back to of marrow think can how the do the closely the more biology tie a together. bit at more

Patrick Trojer

I want to Well, we you said connect of think to mechanism clinical benefit the have it, the action seen. we that

MANIFEST marrow the for And the patients on for data treated bone myeloid of of them. the as we'll as report with of in by reviewed Jigar on reviewed we CPI-XXXX. report, have of said, of seen that these marrow subset changes fibrosis be we the a also able will centrally subset some pathology patients, the patients across bone disclosure, think set be So locally will I wide to ASH a

Jigar Raythatha

part of to CPI-XXXX there just question what's start in special mentioned of second terms data really the it required Brian, think And your for very of be. will that of is the then, to these kind ultimately, we disease. us important how in redemonstrate think dataset. it's think this is to that that. to regulatory will as to allow But we and spleen the because growing important be potential I like to call, a symptoms, will Again, be the of And modify we add the the ultimately, able about approval. But course beginning it's

Brian Abrahams

or statistical curious and speaking need respect X just there? to resizing hit score to the of then latest symptoms, views And And interim it. MANIFEST with to enable from curious powering on not of on designing your your drugs to I'm also Got precedent symptom potential recent significance an whether as endpoint. other that MF you if view changes

Jigar Raythatha

Are you to referring pacritinib?

Brian Abrahams

Yes.

Jigar Raythatha

Yes.

an in landscape, as Just watching development carefully we'll it be definitely, to positive mean, regulatory and I take it the think, I and that, interesting unfolds.

needed. regard with we've would on data any pretty as the well robustly. good design data to to it's a base date. to to have case our here else job and ourselves of a that more on changed has today make think approaching given kind as nothing the That's I we power to assumptions be out and -- been flexibility continue for And on. done so as how But eye think was the laid will from with of really we how don't kind sets something III And outlined. the possible. that that resize I to And details we've we be, design has path always always Phase study We keep we've continue historical added the generated been that has that course, details an we'll we're will think trial of powering. explore the later And if pretty decision. the is of anything a

Brian Abrahams

in. it squeeze it. Got I And one, if quick more could just one

to other HDACs. additional MANIFEST I the impact just or timing significance around On future I'm if the work changes all have modulators of the sort consent curious might X start of seen any like know that label? that's it or genotoxicity, for any inform that's with epigenetic something

Jigar Raythatha

Yes.

So comment kind that there's to as you Patrick, want but we to through I do work more impacts work. I may it course. if, noted nonclinical you don’t Nothing certainly of going signal, that more the would think Q, of the to on on normal critical are we're in know timelines was the understand and path, various any that? any think pretty

Patrick Trojer

Yes.

the agree completed I genotox package haven't yet. with We you.

think this the us that point from we timelines. like I makes at that nothing there's feel deviate

Operator

Ulz Mike with question And comes our from Baird. next

Mike Ulz

on quick I just follow-up had a MANIFEST study. the X

it soon. start fairly on So guys that are like track you to seems

you if just around So thoughts can share I'm maybe curious your enrollment timelines.

had you've MANIFEST? that Now experience with

Jigar Raythatha

Jeff, one? you take do to this want

Jeff Humphrey

Jigar. Thanks, timelines -- sure. learned Yes, was anticipate there for you slowdown a during lot. accrual. that currently which disclosing Mike, we're accrued accrue as well. expected well. We We we MANIFEST X will MANIFEST now, not we Right full during know, COVID

Operator

comes next Jefferies. Biren question Amin Our from with

Biren Amin

to drivers Maybe still X. study? in for to Can just the you the MANIFEST on in additional lead overlap talk adaptive what's what feature target of XXX to would MANIFEST the II to trial? about start enroll? guess, compared clinical Phase whether the I there's then And you And do patients from sites enrolling X design an expect

Jigar Raythatha

for question. your Thanks

So first of all, I powering robust at the think we've done a job really study.

based that want as a we've are given single-arm raised earlier, on fact that if the we our think that that on TSS the study. we'll to However, size, flexibility increase for to the question we assumptions making was powering do to ourselves

assumptions us we've needed. made. a like to We if with job flexibility it's on that just give good feel that done we've the So really it's the pretty

there's additional point this information of no be that that how and on. made terms when we would decision of have kind So at in

Biren Amin

Do study. at what I Can expect path you Do feel there? the then ASH, I guess, And the line indication? patients feel you that maybe data on your an XX be Okay. be XX for in about, to additional weeks. think second-line sufficient you you'll talk X that to that, to maybe would second that forward inform you steps next have you at in

Jigar Raythatha

Yes.

concluded what around and We've line. So kind in we that to for of data second the focus at And the of us first line XXX is we entirety commercial regulatory of been to we're the in right about of really careful day, presenting -- patient. the taken to do the the work end we've right path be our the package look that think a excited kind forward. naive at study registration

ruxolitinib that be similar cover Our label label the and label could is had. expectation would achieve first fedratinib patients a broad we and that to would line second that the that

registration in seeing of been hopefully, drive cohorts excited study we'll to second said ultimately, second-line currently that in the really some drive Having that that, reimbursement. about we're not But so results the enroll patients those publications are to to planning And continue we another line context. setting. we've in and do

Operator

question Our from next Srikripa comes Securities. with Devarakonda Truist

Srikripa Devarakonda

associated for giving that in looking to any be that initiating that data a site some that in enrollment pandemic. about some cadre, are in and that mentioned were MANIFEST. collection that with also instances combos of that You to competition other X? competitors to you're and sites MANIFEST, any you to what there in of ensure considering of collection data the MANIFEST delays pivotal talk incomplete expectations is to given maybe you question, in there ongoing rux could your of What you trials, there complete the be us place your also talk collection? data COVID, at and barring And would delays complete sort pointers what other sort filings Can sort sites ensure package have the another

Jigar Raythatha

Srikripa, thanks question. for your

our First, on timing, we believe from that patient that. a previous question We have agents. investigators I provided nothing your population with, that the the maybe that for first-line most a just setting perspective III. the doubling other really among I MANIFEST of we'll is there experience sites of competitively should there's that we second have lot well up And it think We new more in and first. in lot take that us Phase experience the we dataset on guidance robust -- we with. have and had XX-plus out We position sites our end accrual, study, than in a

the about feel to ability excited really do And so that. we

-- couple III years I of the Phase for a the we into data, continues think and right. think start feel about finish in to patient from to deal said that past, we first So

again? So of first can question part you your repeat the

Srikripa Devarakonda

in your mentioned you there in collection data MANIFEST. filings, were So instances of some that incomplete

So place that in sort to wondering have pivotal. doesn't guardrails to of what I happen you ensure was

Jigar Raythatha

Yes. Yes.

kind So a spring they there -- couple around to not -- in may who There of new, -- something the kind way. were the it's space were in nothing when of but patients we were patients wasn't the was the all is shutdowns weren't patients, it when by COVID. of couple This of -- were a that of that have there missed here scans. and there heat

we And and for put so gets were reported. sure together able data make to to that guidance collected how

And that, of to -- COVID-related of practice and that was the in number able date use that shutdowns it deal There's if be impute there's been point. a XX of so of, the kind good time to where weeks instance, another some good the for data future. the the also of can for -- weeks there to collected. we'll actual flexibility after location is already that There's on and with prior and to on flexibility be

we So use that we'll those MANIFEST MANIFEST, work to procedures in able X. and same nicely there's -- through be in

Operator

next and with Our comes Kenneth Company. from question Atkins Cowen

Kenneth Atkins

number in study point? patients? of only enrollment resizing that progressing? X, are MANIFEST could analysis, you that is to Or at of of provide expand interim the at terms terms do And how the point For target the to the you able in allow for plan lowering updates

Jigar Raythatha

making to -- interim. mean, best point do there. of we're it's think decisions I kind kind at on of an I about Kenneth, any to talk final what kind So We're still ready not this of

can discussion. for maybe later so we a And that save

Kenneth Atkins

Got it.

noticed tumors as an there. the added liquid that that for XXXX, Phase now II Okay. study pursued we And indication of be could you've

have you tumors? Just solely assessment solid on might the the decision wondering focus what that reconsider to changed of made in your opportunity

Jigar Raythatha

Yes. been fit us very continue the molecule in in about to to we and natural think Nothing build. as has consider have for And biologically exciting infrastructure mean, I with it's hematology a advantage I rose, itself. EZHX like there opportunities biology. our liquid company nice tumors take And there's we'll profile changed of the other that lymphoma. to always EZHX

Operator

with Markets. from question Kim Do next BMO Capital Our comes

Guyn Kim

First, the standard looks you of on what opportunity your expansion or population like who patient in to of speak failed terms addressable care into that and those are ET, more could it. on

Jigar Raythatha

Jeff. question. turn your going from then this I'll saying for just to and over that I'll Maybe Thanks study. start, we're be start to by I'll it learning

I think that ET. no base there's therapy approved -- today for

I -- the patients. previous criteria focused think we think not of the really inclusion have have set studies on right are what

And more what patients are about really to a But here then. -- maybe, is And add of we're do so trying what you to who could I we're part those can more identify talk endpoint about and the Jeff, the that. would be. opportunity bit

Jeff Humphrey

Yes. Thanks, Jigar.

We're would that essential disease response response a would high And the of symptoms. and done like looking So refractory the with very platelet include present our be as counts trial at XXX population a events headache signal and has symptoms as and thrombosis, is be MPN-SAF. high with symptoms, thrombocythemia within reduction hematologic counts. things for certainly platelet of and looking platelets one And of including of such efficacy, effects. patients for complete consequences its this and bleeding look to hydroxyurea

Jigar Raythatha

Yes. And think it side but work we're the to still doing opportunity overall some on significant. the be pretty understand could commercial we

Guyn Kim

in -- if in whether considering updated decision Europe? And question had what U.S. what thoughts your EU a partner factors to another your strategy, on you're on you Great. ex any for plans study? are an And on

Jigar Raythatha

Yes. Yes.

a we'll execute So it study I designed from is globally. the the think on to believe perspective, to drive we we've approvals to And regulatory correct address study that.

from kind don't study perspective, help to on the -- to need assistance the us to a player we from execute So drive partnering a approvals. global to of get and global

think I question. it's commercially, different Now a

the We that I help to we think would it's U.S., point have yet seek but that, us to that a assume a do have reasonable quite not build decision partner the outside infrastructure not decision. made to we some yet, a made company, as commercial at that

Operator

JMP with Securities. Our next Ren from Benjamin question comes

Ren Benjamin

X, you is maybe the on X just over Or mix Is response kind over is what progress. for Can impact of patients time, might time? controlled? bit data post being trying how might noticed just much we might a And patients? question, Congrats about rates it it -- a in heterogeneous sense I me. see look? maybe to And of second I a little talk at guess not adequately it as trial how PV that guess includes that patients. get a of ASH? the MANIFEST And I'm and ET maybe XX-week we

on to these patients? thoughts know treated kind primary patients MF your for And differ your the interested experience And so patients combination? from how been those I'm of with been what's

Jigar Raythatha

Yes.

So kind patients now subset start who got the to a that. I at response. that durability I on of long been can of have look enough we've therapy the mean, the think we of

hearing. setting. very we've and feel seeing think that we're of on perspective. effects and kind refractory those a a durability -- this seen I patients of the from also including for from kind from qualitatively been what over the from durability that And years. our is second-line some patient thick have just patients pleased we've X then population We of pretty been about That

some upcoming of fair the ASH at start it's update. think that to I to we that So can examine data say

pretty pleased. can think post I regard far, post mentioned, more to start -- so and quantify we qualitatively, that. and With and least as we we're get primary. to start PV experience, I ET at as more to And

types, that similar systemic all to of have patients treated therapies. MF we've previous think I studies

responding. in haven't of jump the high. difference major out have pretty as kind a how anything response those seen think overall are been rates patients Again, I we

PV signal that primary So post not in a from clear MF. ET, separation and post

Operator

Instructions]. [Operator

comes Our with Oppenheimer. from next Olson question Jay

Jay Olson

you finally, escalation comments some additional on a wondering combination also, about? will this only that then Can synthetic was what color you is combination? lethality. dose I tolerability And And you're maybe XXX. most that on the few potential drug I Or you for monotherapy? safety used profile provide any that then XXX XXX with be that hypothesis? will seeing study? a in I developed as the be a excited the in mentioned And on share think and Could had you're

Jigar Raythatha

help. to Patrick start I'll So also but solicit

safety of get kind that and is apply details, are to to into a RPXD was and dose we of update about dose and of we a can’t key I kind looking the escalate that. tolerated perspective, kind the I implied Patrick's but continuing then component thinking of from there the So maximum think

think well we're pretty in mechanism. I a safety this from perspective So doing

previous tends I can context, very demonstrated about be war be bit kind little that kind of combinations seems the fascinating. expression. experience lethality to monotherapy of of There about you And tolerated. of other think activity. to do Maybe, talk potential tug of with to gene as as Patrick, a is and -- very the -- a kind we've I get on well some then our with think, synthetic XXXX want for questions well

Patrick Trojer

Thanks, questions. Yes. all Sure. Jay, the for

performance the happy profile date. we're Jigar safety said, as So about of and really to the CPI-XXXX

start other MTD, midst the on that hypothesis some guided we Phase that and around have determine expansion hypothesis of primarily in once well We the biomarker comment we in into multiple increases by nice we markers. as safety we designed have assessed as study really II. study the the all-comers molecularly can interest study and really in that with some to We cohorts still seen that of pharmacodynamic increasing the cohorts, answering the Since this PD dose-dependent the we questions we further an for exposure, get the --they're an shown escalating, have can't of hypothesis dose was expansion in. ARIDXA designed particular of levels built as we get hope

finalized As we to have the the open combination a but development question so our combination, we regarding plans plan. as have yet, monotherapy cohorts completely planned well expansion as haven't -- for our

think point, there would but So monotherapy opportunities are as this CPI-XXXX also combination. in for we at

Operator

further any would Raythatha the I'm this not showing turn Jigar to now for at questions call back over remarks. time. I closing to like

Jigar Raythatha

taking Well, much. to wanted time to question. everyone our the a to thank you listen thank ask I call, very for

ASH, into patients I our think of ahead progressing as we our data months new of as we've plenty got and execution us fruition to with XXX of a very bringing for well couple towards head pipeline. on exciting progress as

So again, talking again soon. look to you thanks and everyone, to forward all

Operator

participating. call. this you Ladies conference Thank today's and gentlemen, concludes for

stand You Speakers, by. disconnect. may now please

Constellation Pharmaceuticals (CNST) 1 Nov 202020 Q3 Earnings call transcript